合并微血管侵犯的肝癌肝移植受者的预后评价

梁梓明; 叶林森; 唐晖; 宋来恩; 顾世杰; 易述红

doi:10.3969/j.issn.1674-7445.2020.03.005

合并微血管侵犯的肝癌肝移植受者的预后评价

doi: 10.3969/j.issn.1674-7445.2020.03.005

510630 广州，中山大学附属第三医院肝移植中心

基金项目:

国家自然科学基金 81600505

广东省自然科学基金 2016A030313224

中国博士后科学基金资助项目 2019TQ0369

详细信息

作者简介:
梁梓明，男，1993年生，硕士研究生，研究方向为肝移植、肝癌，Email：liangzim@163.com

通讯作者:
易述红，男，1973年生，博士，主任医师，博士研究生导师，研究方向为肝移植、肝癌，Email：yishuhong@163.com

中图分类号: R617
计量
- 文章访问数: 243
- HTML全文浏览量: 113
- PDF下载量: 20
- 被引次数: 0
出版历程
- 收稿日期: 2020-01-30
- 网络出版日期: 2021-01-19
- 刊出日期: 2020-05-15

Evaluation of clinical prognosis of liver transplant recipients of hepatocellular carcinoma complicated with microvascular invasion

Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information

Corresponding author: Yi Shuhong, Email: yishuhong@163.com

摘要

摘要: 目的探讨合并微血管侵犯（MVI）的肝细胞癌（肝癌）肝移植受者的预后情况。方法通过美国国立癌症研究所的监测、流行病学和最终结果（SEER）数据库提取行肝移植术的3 447例肝癌受者的临床资料。根据受者有否MVI分为MVI组（376例）和无MVI组（3 071例）。分析比较两组肝移植受者的预后情况，包括术后1、3、5年总生存率（OS）及肝癌特异生存率（LCSS）。纳入两组受者的相关临床资料，包括年龄、性别、人种、病理分化、肿瘤大小、淋巴结转移、远处转移、肿瘤-淋巴结-转移（TNM）分期、MVI，采用多因素Cox模型分析肝癌肝移植受者预后的独立危险因素。绘制预测受者预后的列线图，通过一致性指数评价模型准确度。结果无MVI组受者术后1、3、5年OS和LCSS分别为93.5%、82.1%、75.3%和98.3%、93.8%、90.7%，明显高于MVI组的88.8%、72.1%、68.4%和95.3%、83.1%、80.4%（均为P < 0.05）。多因素回归分析显示病理分化、肿瘤大小、淋巴结转移、远处转移、TNM分期以及MVI均是影响肝癌肝移植受者OS与LCSS的独立危险因素（均为P < 0.05）。列线图一致性指数为0.624（0.602~0.648）。结论 MVI是肝癌肝移植受者预后的独立危险因素，与受者预后不良显著相关，以此为基础构建的列线图可预测患者预后情况。
- 肝细胞癌 /
- 肝移植 /
- 微血管侵犯 /
- 预后 /
- 危险因素 /
- 总生存率 /
- 肝癌特异生存率
Abstract: Objective To investigate the clinical prognosis of the liver transplant recipients diagnosed with hepatocellular carcinoma (HCC) complicated with microvascular invasion (MVI). Methods Clinical data of 3 447 HCC recipients undergoing liver transplantation were extracted from Surveillance, Epidemiology, and End Results (SEER) database of American National Cancer Institute. According to the incidence of MVI, all recipients were divided into MVI (n=376) and non-MVI groups (n=3 071). The clinical prognosis of liver transplant recipients was statistically compared between two groups by analyzing the 1-, 3- and 5-year overall survival (OS) and liver cancer specific survival (LCSS). Relevant clinical data including age, gender, race, pathological staging, tumor size, lymph node metastasis, distant metastasis, tumor-node-metastasis (TNM) staging and MVI were recorded in two groups. The independent risk factors of clinical prognosis of HCC recipients undergoing liver transplantation were analyzed by multivariate Cox regression model. The nomogram for predicting the clinical prognosis of the recipients was delineated. The accuracy of the prediction model was evaluated by the consistency index. Results In the non-MVI group, the 1-, 3-, 5-year OS and LCSS were 93.5%, 82.1%, 75.3% and 98.3%, 93.8%, 90.7%, significantly higher than 88.8%, 72.1%, 68.4% and 95.3%, 83.1%, 80.4% in the MVI group (all P < 0.05). Multivariate regression analysis showed that pathological staging, tumor size, lymph node metastasis, distant metastasis, TNM staging and MVI were the independent risk factors of OS and LCSS in HCC recipients undergoing liver transplantation (all P < 0.05). The nomogram consistency index was calculated as 0.624 (0.602-0.648). Conclusions MVI is an independent risk factor of the clinical prognosis of HCC recipients undergoing liver transplantation, which is significantly correlated with poor prognosis of the recipients. The nomogram based on MVI can predict the clinical prognosis of these recipients.
- Hepatocellular carcinoma /
- Liver transplantation /
- Microvascular invasion /
- Prognosis /
- Risk factor /
- Overall survival /
- Liver cancer specific survival

HTML全文

图 1 两组肝癌肝移植受者的生存曲线

Figure 1. Survival curves of liver transplant recipients of hepatocellular carcinoma in two groups

下载: 全尺寸图片幻灯片

图 2 预测肝癌肝移植受者预后的列线图

Figure 2. Nomogram for predicting the prognosis of liver transplant recipients of hepatocellular carcinoma

下载: 全尺寸图片幻灯片

表 1 影响肝癌肝移植受者OS及LCSS的危险因素分析

Table 1. Analysis of risk factors affecting OS and LCSS in liver transplant recipients of hepatocellular carcinoma

参数	OS		LCSS
参数	HR^①（95% CI^②）	P值	HR（95% CI）	P值
年龄	0.887(0.767~1.027)	> 0.05	0.873(0.656~1.188)	> 0.05
性别	0.876(0.755~1.016)	> 0.05	1.016(0.766~1.348)	> 0.05
人种	0.986(0.902~1.077)	> 0.05	1.057(0.669~1.668)	> 0.05
AFP	1.168(1.012~1.348)	> 0.05	0.900(0.669~1.211)	> 0.05
病理分化	1.701(1.413~2.049)	< 0.05	2.940(2.203~3.924)	< 0.05
肿瘤大小	1.063(0.991~1.141)	< 0.05	1.284(0.918~1.795)	< 0.05
淋巴结转移	1.534(1.026~2.016)	< 0.05	1.716(1.213~3.165)	< 0.05
远处转移	1.590(1.042~2.205)	< 0.05	1.793(1.301~3.241)	< 0.05
TNM分期	1.735(1.282~2.348)	< 0.05	3.050(1.979~4.701)	< 0.05
MVI	1.388(1.154~1.669)	< 0.05	2.098(1.580~2.785)	< 0.05
注：①HR为风险比。 ②CI为可信区间。

下载: 导出CSV

参考文献(26)

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492.
[2]	YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604. DOI: 10.1038/s41575-019-0186-y.
[3]	谭晓宇, 陈晓兰, 林金铭, 等.机械灌注技术引领器官捐献与移植模式的变革——器官ICU时代即将到来?[J].器官移植, 2019, 10(4):453-458.DOI:10.3969/j.issn. 1674-7445.2019.04.018. TAN XY, CHEN XL, LIN JM, et al. Mechine perfusion technology leads the transformation of organ donation and transplantation model: the age of organ ICU?[J]. Organ Transplant, 2019, 10(4):453-458. DOI: 10.3969/j.issn.1674-7445.2019.04.018.
[4]	POMMERGAARD HC, ROSTVED AA, ADAM R, et al. Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry[J]. HPB (Oxford), 2018, 20(8):768-775. DOI: 10.1016/j.hpb.2018.03.002.
[5]	胡月雷, 孙大伟, 骆飞翔, 等.单发肝细胞癌发生微血管侵犯的影响因素及预后分析[J].临床肝胆病杂志, 2018, 34(9):1911-1916.DOI: 10.3969/j.issn.1001-5256.2018.09.017. HU YL, SUN DW, LUO FX, et al. Influencing factors for microvascular invasion in patients with single hepatocellular carcinoma and their prognosis[J]. J Clin Hepatol, 2018, 34(9):1911-1916. DOI:10.3969/j.issn. 1001-5256.2018.09.017.
[6]	SUMIE S, KUROMATSU R, OKUDA K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors[J]. Ann Surg Oncol, 2008, 15(5):1375-1382. DOI: 10.1245/s10434-008-9846-9.
[7]	SAYINER M, GOLABI P, YOUNOSSI ZM. Disease burden of hepatocellular carcinoma: a global perspective[J]. Dig Dis Sci, 2019, 64(4):910-917. DOI: 10.1007/s10620-019-05537-2.
[8]	BERTUCCIO P, TURATI F, CARIOLI G, et al. Global trends and predictions in hepatocellular carcinoma mortality[J]. J Hepatol, 2017, 67(2):302-309. DOI: 10.1016/j.jhep.2017.03.011.
[9]	XU X, CHEN J, WEI Q, et al. Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition) [J]. Hepatobiliary Pancreat Dis Int, 2019, 18(4):307-312. DOI: 10.1016/j.hbpd.2019.06.010.
[10]	BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4):302-310. DOI: 10.6004/jnccn.2019.0019.
[11]	GALLE PR, FORNER A, LLOVET JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019.
[12]	AZOULAY D, AUDUREAU E, BHANGUI P, et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma: a multicenter, western, intent-to-treat cohort study[J]. Ann Surg, 2017, 266(6):1035-1044. DOI: 10.1097/SLA.0000000000001986.
[13]	ASSALINO M, TERRAZ S, GRAT M, et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion[J]. Transpl Int, 2020, DOI: 10.1111/tri.13586 [Epub ahead of print].
[14]	YE L, KRIEGL L, REITER FP, et al. Prognostic significance and functional relevance of olfactomedin 4 in early-stage hepatocellular carcinoma[J]. Clin Transl Gastroenterol, 2020, 11(1):e00124. DOI: 10.14309/ctg.0000000000000124.
[15]	SHEN JY, LI C, WEN TF, et al. Liver transplantation versus surgical resection for HCC meeting the Milan criteria: a propensity score analysis[J]. Medicine (Baltimore), 2016, 95(52):e5756. DOI: 10.1097/MD.0000000000005756.
[16]	LI X, HUANG L, LENG X. Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation[J]. J Cancer Res Clin Oncol, 2018, 144(12):2465-2474. DOI: 10.1007/s00432-018-2756-8.
[17]	LAHAN-MARTINS D, PERALES SR, GALLANI SK, et al. Microvascular invasion in hepatocellular carcinoma: is it predictable with quantitative computed tomography parameters? [J]. Radiol Bras, 2019, 52(5):287-292. DOI: 10.1590/0100-3984.2018.0123.
[18]	ANDREOU A, BAHRA M, SCHMELZLE M, et al. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation[J]. Clin Transplant, 2016, 30(7):819-827. DOI: 10.1111/ctr.12755.
[19]	EGUCHI S, TAKATSUKI M, HIDAKA M, et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection[J]. World J Surg, 2010, 34(5):1034-1038. DOI: 10.1007/s00268-010-0424-5.
[20]	GOH BK, CHOW PK, TEO JY, et al. Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma[J]. J Gastrointest Surg, 2014, 18(8):1477-1485. DOI: 10.1007/s11605-014-2542-0.
[21]	YANG P, SI A, YANG J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery, 2019, 165(4):721-730. DOI: 10.1016/j.surg.2018.09.016.
[22]	GIARD JM, MEHTA N, DODGE JL, et al. Alpha-fetoprotein slope > 7.5 ng/ml per month predicts microvascular invasion and tumor recurrence after liver transplantation for hepatocellular carcinoma[J]. Transplantation, 2018, 102(5):816-822. DOI: 10.1097/TP.0000000000002094.
[23]	IGUCHI T, SHIRABE K, AISHIMA S, et al. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation[J]. Transplantation, 2015, 99(6):1236-1242. DOI: 10.1097/TP.0000000000000489.
[24]	NITTA H, ALLARD MA, SEBAGH M, et al. Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation[J]. Surgery, 2019, 165(6):1168-1175. DOI: 10.1016/j.surg.2019.01.012.
[25]	REGINELLI A, VANZULLI A, SGRAZZUTTI C, et al. Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies[J]. Med Oncol, 2017, 34(5):93. DOI: 10.1007/s12032-017-0949-7.
[26]	FAN J, YANG GS, FU ZR, et al. Liver transplantation outcomes in 1, 078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China[J]. J Cancer Res Clin Oncol, 2009, 135(10):1403-1412. DOI: 10.1007/s00432-009-0584-6.